Home Infusion for Rheumatoid Arthritis: Remicade, Biologics, and What to Expect

Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes joint inflammation, pain, and progressive damage if not adequately treated. For patients with moderate-to-severe RA who have not responded to conventional disease-modifying drugs (DMARDs), IV biologic therapies, most commonly Remicade (infliximab), are a cornerstone of long-term disease management.

Receiving these infusions through home infusion therapy is an established option for appropriate patients, eliminating the need for repeated trips to an infusion center. Pharmko provides IV biologic therapy for rheumatoid arthritis across 22+ states with full nursing and clinical support.

How IV Biologics Work for Rheumatoid Arthritis

Biologic medications for RA are engineered proteins that target specific components of the immune response driving joint inflammation. Unlike conventional DMARDs (methotrexate, hydroxychloroquine), which suppress the immune system broadly, biologics block precise inflammatory pathways, allowing for more targeted disease control with a different side effect profile.

The most common IV biologics used in rheumatoid arthritis include:

Remicade (infliximab)

Remicade targets tumor necrosis factor-alpha (TNF-α), a key driver of joint inflammation in RA. It is given by IV infusion at weeks 0, 2, and 6 for induction, then every 8 weeks for maintenance. Remicade is often combined with methotrexate to reduce the formation of anti-drug antibodies and improve long-term efficacy.

Orencia (abatacept)

Orencia works differently from TNF inhibitors, it blocks T-cell activation, an earlier step in the inflammatory cascade. It is administered monthly by IV infusion after a loading dose schedule at weeks 0, 2, and 4. Orencia is often preferred for patients who have not responded to or tolerated TNF inhibitors.

Actemra (tocilizumab)

Actemra targets the interleukin-6 (IL-6) receptor, blocking a cytokine that plays a central role in RA inflammation and systemic symptoms including fatigue and anemia of chronic disease. It is given every 4 weeks by IV infusion. Actemra is also used as monotherapy (without methotrexate) in patients who cannot tolerate conventional DMARDs.

Who Qualifies for Home Infusion of IV Biologics for RA?

Home infusion of IV biologics for rheumatoid arthritis is appropriate for patients who:

Have received at least their first two to three infusions in a supervised clinical or infusion center setting to screen for infusion reactions
Are on a stable, maintenance dose without recent significant reactions
Have been assessed by their rheumatologist as clinically stable for home-based administration
Have a home environment that supports safe IV administration

Patients who are newly starting a biologic, have a history of serious infusion reactions, or have active infection or significant immunosuppression typically require supervised infusions until their clinical situation is established.

What a Home Biologic Infusion for RA Looks Like

Before the infusion

Your rheumatologist confirms your next infusion is due and submits orders to Pharmko. Our team verifies your insurance coverage, prepares your medication, and schedules a nursing visit. Before the infusion begins, your Pharmko nurse reviews your current medications, checks for signs of active infection, and takes baseline vital signs. Pre-medications (acetaminophen, antihistamine, or corticosteroid) may be given per your rheumatologist's orders.

During the infusion

Infusion duration varies by medication: Remicade typically takes 2 hours, Orencia approximately 30 minutes, and Actemra about 1 hour. Your nurse monitors your vital signs throughout and is present to respond immediately to any reaction. The rate may be slowed if you experience any discomfort.

After the infusion

Your nurse documents the session and communicates with your rheumatologist's office. You will be monitored briefly before the nurse leaves. Know which symptoms should prompt a call in the hours and days after your infusion, delayed reactions can occur with biologics, and our 24/7 after-hours support line is available around the clock.

Managing Infection Risk on IV Biologics

All IV biologics used in RA suppress components of the immune system, which increases susceptibility to infection. Before starting or continuing biologic therapy, your rheumatologist will typically screen for tuberculosis, hepatitis B, and ensure vaccinations are up to date.

During home infusion therapy, contact Pharmko immediately if you develop fever, new respiratory symptoms, skin infections, or any symptoms that seem unusual. Do not wait until your next scheduled infusion. Infection risk is one of the primary reasons biologics require ongoing clinical supervision even when administered at home.

Remicade for RA vs Crohn's Disease

Remicade is FDA-approved for both rheumatoid arthritis and inflammatory bowel disease. While the mechanism is the same, TNF-α inhibition, the dosing, monitoring, and clinical context differ between these indications. For patients managing both RA and GI conditions, or for providers comparing these use cases, our guide on home infusion for Crohn's disease covers the IBD-specific context in detail. A broader overview of IV biologics across autoimmune conditions is available in our article on home infusion for autoimmune diseases.

Insurance Coverage for Home Biologic Infusions

IV biologics for rheumatoid arthritis are typically covered under the medical benefit — not the pharmacy benefit — by Medicare Part B and most commercial insurance plans when administered by a licensed provider. Prior authorization is required and must document clinical indication, prior DMARD history, and current disease activity. Pharmko manages the full authorization process and will communicate any coverage concerns before your first home infusion.

Step therapy requirements, where insurers require trial and failure of less expensive agents before approving a biologic, are common. Pharmko's authorization team is experienced with RA-specific step therapy documentation and can support your rheumatologist in building the necessary clinical record.

Getting Started

If you or your patient is on a stable IV biologic for rheumatoid arthritis and interested in transitioning to home infusion, the first step is a referral from your rheumatologist. Pharmko works with rheumatology practices across 22+ states and can typically initiate therapy within 24–72 hours of referral acceptance.

→ Submit a referral or contact Pharmko : 1-877-540-2003 · info@pharmko.com

< Older Post

Newer Post >

Compounded IV Medications: When Are They Necessary and How Are They Made?

July 15, 2026

Most medications that patients receive at a hospital or pharmacy come in standardized, commercially manufactured forms, a 500mg antibiotic vial, a pre-filled syringe, a fixed-concentration IV bag. These products work well for many patients. But a significant portion of patients receiving IV therapy have clinical needs that commercial products cannot meet: a dose the manufacturer doesn't make, a formulation incompatible with the patient's allergy profile, or a combination of nutrients that must be tailored to individual lab values. For these patients, compounded IV medications are not optional, they are clinically necessary. Pharmko's sterile compounding services prepare customized IV medications for patients across 22+ states, with every formulation reviewed by a licensed pharmacist and prepared in a USP <797> compliant cleanroom. What Makes an IV Medication 'Compounded'? A compounded medication is one that is prepared specifically for an individual patient by a licensed pharmacist, rather than manufactured in bulk by a pharmaceutical company. Compounding involves combining, mixing, or altering ingredients, active pharmaceutical ingredients, diluents, preservatives, to create a final preparation that meets the patient's unique prescription requirements. For IV therapy specifically, compounding means preparing a sterile preparation, one that is completely free of viable microorganisms and safe to inject or infuse directly into the bloodstream. This requires specialized facilities, equipment, training, and quality systems that go far beyond what a standard retail pharmacy can provide. Pharmko is exclusively a sterile compounding pharmacy. We do not compound oral medications, topical creams, or non-sterile preparations. Every product we make is intended for intravenous, intraperitoneal, or subcutaneous administration. When Are Compounded IV Medications Necessary? The required dose doesn't exist commercially Pharmaceutical manufacturers produce medications in standardized strengths and volumes based on average patient needs. Pediatric patients, patients with renal or hepatic impairment requiring dose adjustments, or patients whose weight or clinical status falls outside standard ranges may need concentrations or volumes that no commercial product provides. Compounding fills this gap precisely. The patient has an allergy to a commercial formulation's inactive ingredients Commercial IV products often contain preservatives, stabilizers, or diluents, sulfites, benzyl alcohol, certain dyes, that some patients cannot tolerate. A compounding pharmacy can prepare an equivalent formulation without the offending ingredient, allowing the patient to receive the therapy safely. The medication requires individualized nutrient formulation Total parenteral nutrition (TPN) is the clearest example: every TPN formula must be individually compounded because no commercial product can provide the precise combination of amino acids, dextrose, lipids, electrolytes, vitamins, and trace minerals a specific patient needs. The formula changes as the patient's labs, weight, and clinical status change, making standardization impossible. The commercial product is unavailable or in shortage Drug shortages are a persistent reality in the US pharmaceutical supply chain. When a commercially manufactured IV medication becomes unavailable, compounding pharmacies can often prepare an equivalent formulation from available active pharmaceutical ingredients, bridging the gap and maintaining continuity of therapy for patients who cannot wait. The therapy requires a custom delivery format Some IV medications require specific pH, osmolarity, or concentration adjustments for compatibility with a patient's IV access device or concurrent medications. A compounding pharmacist reviews compatibility and prepares formulations that are safe and stable for the specific administration route and equipment the patient is using. How Compounded IV Medications Are Made Step 1: Prescription review Every compounded IV medication begins with a valid prescription from a licensed prescriber. Pharmko's pharmacists review the prescription for clinical appropriateness, dosing accuracy, ingredient compatibility, and stability before compounding begins. Step 2: Ingredient sourcing and verification Active pharmaceutical ingredients for compounding must come from FDA-registered suppliers and meet USP monograph specifications. Each lot is verified for identity, potency, and purity before use. Step 3: Sterile preparation in a controlled environment Preparation occurs in an ISO Class 5 laminar airflow workbench or biological safety cabinet, located within a buffer room that meets ISO Class 7 air quality standards. Pharmacy technicians follow validated, written procedures for each preparation type, using aseptic technique to prevent contamination at every step. Step 4: Pharmacist verification and release A licensed pharmacist performs a final check of every preparation, verifying appearance, volume, labeling, and documentation, before the product is released. High-risk or complex preparations may undergo sterility testing with defined beyond-use dates based on test results. Step 5: Cold-chain delivery Most compounded IV medications require refrigeration. Pharmko uses validated cold-chain packaging and delivery logistics to ensure products arrive within their stability windows and remain temperature-controlled until the patient uses them. Quality Standards That Matter Not all compounding pharmacies operate at the same standard. The relevant quality benchmarks for sterile compounding are: USP <797> compliance, the national standard for sterile compounding environments, personnel, and processes. Our guide on USP <797> and USP <800> explains what compliance means in practice ACHC accreditation, independent third-party verification that Pharmko meets clinical quality standards for home infusion and sterile compounding State pharmacy board licensure, Pharmko is licensed in every state where we serve patients Environmental and personnel monitoring, documented air and surface sampling, personnel gowning competency assessments, and media fill testing at defined intervals For a foundational overview of what sterile compounding is and how it differs from retail pharmacy, see our guide on what is sterile compounding for IV therapy . → Contact Pharmko about compounded IV medications: 1-877-540-2003